Literature DB >> 18938112

Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation.

Børre Fevang1, Arne Yndestad, Jan K Damås, Vigdis Bjerkeli, Thor Ueland, Are M Holm, Klaus Beiske, Pål Aukrust, Stig S Frøland.   

Abstract

Common variable immunodeficiency (CVID) is a heterogeneous syndrome characterized by defective immunoglobulin production and high frequency of bacterial infections, autoimmunity and manifestations of chronic inflammation. The chemokine Fractalkine (CX3CL1) and its receptor CX3CR1 is suggested to play an important role in the pathogenesis of several inflammatory disorders. We hypothesized that enhanced CX3CL1/CX3CR1 interaction could be involved in the chronic inflammation characterising subgroups of CVID. CVID patients were characterized by raised plasma levels of CX3CLl and enhanced expression of its corresponding receptor CX3CR1 on CD4(+) and CD8(+) T cells, including both CD45RA(+) and CD45RA(-) subsets. CX3CR1 expression was particularly enhanced in patients characterized by chronic inflammation in vivo. The high expression of the receptor in CVID patients was accompanied by enhanced chemotactic, adhesive, and other inflammatory cell responses to stimulation with CX3CL1. Our findings suggest that increased CX3CL1/CX3CR1 interaction could contribute to the inflammatory phenotype seen in subgroups of CVID patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18938112     DOI: 10.1016/j.clim.2008.09.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

1.  Oral microbial biofilm stimulation of epithelial cell responses.

Authors:  Rebecca Peyyala; Sreenatha S Kirakodu; Karen F Novak; Jeffrey L Ebersole
Journal:  Cytokine       Date:  2012-01-21       Impact factor: 3.861

2.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Authors:  Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang
Journal:  Ann Neurol       Date:  2011-03-11       Impact factor: 10.422

Review 3.  Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.

Authors:  Helen Chapel; Charlotte Cunningham-Rundles
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

4.  Fractalkine receptor polymorphism and chronic tonsillitis.

Authors:  Seda Turkoglu Babakurban; Selim S Erbek; Yunus Kasim Terzi; Fatih Arslan; Feride I Sahin
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-05       Impact factor: 2.503

5.  CX3CR1 RNAi inhibits hypoxia-induced microglia activation via p38MAPK/PKC pathway.

Authors:  Yong Liu; Tianzhi Zhao; Zhao Yang; Qianning Li
Journal:  Int J Exp Pathol       Date:  2014-04       Impact factor: 1.925

6.  Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation.

Authors:  B Fevang; A Yndestad; J K Damås; B Halvorsen; A M Holm; K Beiske; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2009-08-12       Impact factor: 4.330

7.  Expression of chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes from patients with primary antibody deficiency.

Authors:  D Payne; S Drinkwater; R Baretto; M Duddridge; M J Browning
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

8.  Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis.

Authors:  Jeffrey H Mills; Leah M Alabanza; Deeqa A Mahamed; Margaret S Bynoe
Journal:  J Neuroinflammation       Date:  2012-08-10       Impact factor: 8.322

9.  Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients.

Authors:  Thomas R Cimato; Beth A Palka
Journal:  Clin Transl Med       Date:  2014-06-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.